ID   LNZTA3WT4
AC   CVCL_3540
SY   LNZTA3p53WT4; WT4
DR   CLO; CLO_0007371
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 931
DR   BioSample; SAMN03471340
DR   cancercelllines; CVCL_3540
DR   Cell_Model_Passport; SIDM01220
DR   Cosmic; 1995487
DR   Cosmic-CLP; 1240170
DR   DepMap; ACH-002269
DR   EGA; EGAS00001000978
DR   GDSC; 1240170
DR   GEO; GSM1670052
DR   LINCS_HMS; 50028
DR   LINCS_LDP; LCL-1345
DR   PharmacoDB; LNZTA3WT4_853_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54902866
RX   Patent=US5807731;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Group: Patented cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11543.
CC   Population: Caucasian.
CC   Characteristics: The expression of the luciferase reporter gene as well as the TP53 gene are under the control of a tetO operator.
CC   Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Transfected with: HGNC; 11998; TP53.
CC   Transfected with: UniProtKB; P08659; Firefly luciferase.
CC   Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR.
CC   Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del).
CC   Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR).
CC   Transfected with: UniProtKB; P00552; Transposon Tn5 neo.
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=1.42%; Native American=1.36%; East Asian, North=1.52%; East Asian, South=0%; South Asian=1.65%; European, North=44.35%; European, South=49.7% (PubMed=30894373).
CC   Derived from site: In situ; Brain, right parieto-occipital lobe.
ST   Source(s): ATCC; Cosmic-CLP
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 9,12
ST   D5S818: 12
ST   D7S820: 10,12
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 15,17
DI   NCIt; C60781; Astrocytoma
DI   ORDO; Orphanet_94; Astrocytoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0394 ! LN-308
SX   Male
AG   60Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 28
//
RX   Patent=US5807731;
RA   Van Meir E.G., Huang H.-J.S., Cavenee W.K.;
RT   "Glioblastoma cell lines that produce angiogenesis inhibiting
RT   factor.";
RL   Patent number US5807731, 15-Sep-1998.
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//